BioCryst Pharma (BCRX) PT Raised to $23 at JMP Securities, Following Earnings
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.81 -7.37%
Rating Summary:
17 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
17 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
JMP Securities analyst Jonathan Wolleben raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $23.00 (from $22.00) while maintaining a Market Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
- Macquarie Upgrades Inventec Corp (2356:TT) to Neutral
- Resideo Technologies (REZI) PT Lowered to $27 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JMP Securities, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
